Diabetic nephropathy

被引:0
作者
Menne, J. [1 ]
Haller, H. [1 ]
机构
[1] Hannover Med Sch, D-30625 Hannover, Germany
来源
INTERNIST | 2011年 / 52卷 / 05期
关键词
Albuminuria; Hypertension; HbA(1c); Renin angiotensin system; Diabetic nephropathy; STRUCTURAL-FUNCTIONAL RELATIONSHIPS; CARDIOVASCULAR EVENTS; RENAL-DISEASE; MICROALBUMINURIA; INTERVENTION; METAANALYSIS; ALBUMINURIA; PROTEINURIA; PREVENTION; MORTALITY;
D O I
10.1007/s00108-010-2761-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy is the most common cause of end-stage renal disease. Since the disease progresses very slowly and usually takes more than 20 years before terminal renal failure occurs, early intervention is of great importance in order to prevent this disabling complication. A good control of diabetes with HbA(1c) levels around 7% is desirable. At least as important is the treatment of elevated blood pressure values. The target value for patients with diabetes has been adjusted in the last year and is now 130-139/80-85 mmHg. Should (micro-)albuminuria or renal insufficiency be present the blood pressure target is < 130/80 mmHg. For the control of hypertension the use of ACE inhibitors or angiotensin receptor blockers is recommended. In addition, the control of other risk factors and appropriate therapeutic intervention is required. A multifactorial intervention leads to the best results and can avoid the occurrence or progression of diabetic kidney disease and other micro- and/or macrovascular complications.
引用
收藏
页码:495 / +
页数:8
相关论文
共 23 条
[1]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[2]  
*BAK, 2010, NAT VERS LEITL NIER
[3]   Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial [J].
Bakris, George L. ;
Sarafidis, Pantelis A. ;
Weir, Matthew R. ;
Dahlof, Bjorn ;
Pitt, Bertram ;
Jamerson, Kenneth ;
Velazquez, Eric J. ;
Staikos-Byrne, Linda ;
Kelly, Roxzana Y. ;
Shi, Victor ;
Chiang, Yann-Tong ;
Weber, Michael A. .
LANCET, 2010, 375 (9721) :1173-1181
[4]   Pathogenesis, prevention, and treatment of diabetic nephropathy [J].
Cooper, ME .
LANCET, 1998, 352 (9123) :213-219
[5]   Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy [J].
Cooper, ME .
DIABETOLOGIA, 2001, 44 (11) :1957-1972
[6]   Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus [J].
Cushman, William C. ;
Evans, Gregory W. ;
Byington, Robert P. ;
Goff, David C., Jr. ;
Grimm, Richard H., Jr. ;
Cutler, Jeffrey A. ;
Simons-Morton, Denise G. ;
Basile, Jan N. ;
Corson, Marshall A. ;
Probstfield, Jeffrey L. ;
Katz, Lois ;
Peterson, Kevin A. ;
Friedewald, William T. ;
Buse, John B. ;
Bigger, J. Thomas ;
Gerstein, Hertzel C. ;
Ismail-Beigi, Faramarz .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) :1575-1585
[7]  
Dalla Vestra M, 2000, DIABETES METAB, V26, P8
[8]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[9]  
Gansevoort R. T., 2011, KIDNEY INT
[10]   Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes [J].
Haller, Hermann ;
Ito, Sadayoshi ;
Izzo, Joseph L., Jr. ;
Januszewicz, Andrzej ;
Katayama, Shigehiro ;
Menne, Jan ;
Mimran, Albert ;
Rabelink, Ton J. ;
Ritz, Eberhard ;
Ruilope, Luis M. ;
Rump, Lars C. ;
Viberti, Giancarlo .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10) :907-917